Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)

NCT03806426 is registered in ClinicalTrials.gov with S.L.A. Pharma AG as lead sponsor.

NCT NCT03806426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03806426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)
Lead sponsor
S.L.A. Pharma AG
Phase
Phase 3
Overall status
Unknown status
Start date
December 5, 2018
Completion date
July 31, 2024
Enrollment
204 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

familial adenomatous polyposis